Administration of sunitinib to patients with non-small cell lung cancer and irradiated brain metastases: A phase II trial.

Abstract

8077 Background: Sunitinib (SU), an oral, multitargeted inhibitor of VEGFRs, PDGFRs, KIT, FLT3, CSF-1R, and RET has promising single-agent antitumor activity in refractory non-small cell lung cancer (NSCLC) (Socinski JCO 2008). Brain metastases (BrMs) occur in ≥25% of NSCLC patients (pts); preclinical data suggest that VEGF signaling is required for the… (More)

Topics

Cite this paper

@article{Novello2009AdministrationOS, title={Administration of sunitinib to patients with non-small cell lung cancer and irradiated brain metastases: A phase II trial.}, author={Silvia Novello and Lauren Eileen Abrey and Francesco Grossi and Carlos Camps and Julien Mazi{\`e}res and Paulina Selaru and Shem Patyna and Yoshitsugu Torigoe and Richard C. Chao and Giorgio Scagliotti}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2009}, volume={27 15_suppl}, pages={8077} }